Satyabrata Meher

Dr. Satyabrata Meher


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SPSiris Patel
Siris Patel
PPPrasanta Purohit
Prasanta Purohit
RMRanjeet Singh Mashon
Ranjeet Singh Mashon
SDSnehadhini Dehury
Snehadhini Dehury
SMSatyabrata Meher
Satyabrata Meher
DPDilip Kumar Patel
Dilip Kumar Patel

24 December 2014 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SDSnehadhini Dehury
Snehadhini Dehury
PPPrasanta Purohit
Prasanta Purohit
SPSiris Patel
Siris Patel
SMSatyabrata Meher
Satyabrata Meher
BKBipin Kishore Kullu
Bipin Kishore Kullu
DPDilip Kumar Patel
Dilip Kumar Patel

19 November 2013 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
DPD. K. Patel
D. K. Patel
PPP. Purohit
P. Purohit
SDS. Dehury
S. Dehury
PDP. Das
P. Das
ADAmbarish Dutta
Ambarish Dutta
KDK. Das
K. Das

3 January 2021 in Hemoglobin
Verified
Journal Article
Closed access
SMSatyabrata Meher
Satyabrata Meher
PMPradeep K. Mohanty
Pradeep K. Mohanty
SPSiris Patel
Siris Patel
KDKishalaya Das
Kishalaya Das
SSSarmila Sahoo
Sarmila Sahoo
PDProf. Bisnu Prasad Dash
Prof. Bisnu Prasad Dash
Sickle cell anemia is hallmarked by hemolysis, which releases hemoglobin (Hb) into the plasma promoting vaso-occlusive crisis (VOC). Haptoglobin (Hp) clears free Hb and decreases Hb-related pathophysiology in sickle cell anemia. There are two alleles (HP1 and HP2) and three genotypes (HP1-1, HP1-2 and HP2-2) of Hp with different frequencies in different populations. This study involved Hp level and genotype among normal and sickle cell anemia patients with varying severity of VOC. A total of 297 sickle cell anemia patients and 98 healthy controls were selected for the study. The sickle cell anemia patients were categorized as ‘mild-phenotype’ with no pain episodes and ‘severe-phenotype’ as having three or more acute pain episodes in the preceding 12 months. The Hp level was significantly lower (p < 0.001) in sickle cell patients anemia than controls; HP1-1 genotype had a higher Hp level compared to HP1-2 and HP2-2 (p < 0.05). Turkey-Kramer multiple comparison tests showed that mild and severe phenotypes have significant differences (p < 0.05) in Hb F%, Hb, platelet count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), direct-bilirubin (Bil-D), total-bilirubin (Bil-T), lactate dehydrogenase (LDH) and Hp level. Pearson correlation revealed that Hp level has a positive (p < 0.05) correlation with Hb F%, Hb, packed cell volume (PCV) and serum urea; in contrast its level is negatively correlated with AST, ALT, Bil-T and LDH. A significantly higher frequency of HP2 allele and HP2-2 genotypes was found in severe phenotypes. In the studied population, it was found that higher HP2 frequency, low Hp level and more hemolysis favors the onset of VOC in sickle cell anemia.

1 June 2017
Verified
Journal Article
Closed access
LSLulup Kumar Sahoo
Lulup Kumar Sahoo
BKBipin Kishore Kullu
Bipin Kishore Kullu
SPSiris Patel
Siris Patel
NPNayan Kumar Patel
Nayan Kumar Patel
PRPragyan Rout
Pragyan Rout
SMSatyabrata Meher
Satyabrata Meher

1 March 2019 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
BJBimal Prasad Jit
Bimal Prasad Jit
PMPradeep Kumar Mohanty
Pradeep Kumar Mohanty
PPPrasanta Purohit
Prasanta Purohit
KDKishalaya Das
Kishalaya Das
SPSiris Patel
Siris Patel
PDPadmalaya Das
Padmalaya Das